RBC Bioscience

RBC Bioscience Financial Leverage

The Financial Leverage (Equity Multiplier) of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 3.06. In the previous year, Financial Leverage (Equity Multiplier) was 3.13 — a change of -2.15% (lower).

Financial Leverage

3.06

YoY

-2.15%

Last updated:

Financial Leverage (Equity Multiplier) of RBC Bioscience is 2024 3.06 . Financial Leverage (Equity Multiplier) of RBC Bioscience was 2023 3.13 . It decreases by -2.15% lower compared to the previous year.

The RBC Bioscience Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.94 TWD
Jan 1, 2019
2.29 TWD
Jan 1, 2020
2.93 TWD
Jan 1, 2021
3.30 TWD
Jan 1, 2022
3.18 TWD
Jan 1, 2023
3.13 TWD
Jan 1, 2024
3.06 TWD
The RBC Bioscience Financial Leverage history
YEARFinancial LeverageYoY
3.06-2.15%
3.13-1.44%
3.18-3.73%
3.30+12.49%
2.93+28.08%
2.29+17.87%
1.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Financial Leverage (Equity Multiplier) of RBC Bioscience is 3.06 in 2024.

Financial Leverage (Equity Multiplier) of RBC Bioscience changed from 3.13 to 3.06, representing a -2.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RBC Bioscience

All Key Metrics — RBC Bioscience